Form 4: Silence Therapeutics Director Richard Ian Griffiths Reports Share Acquisitions

Director Richard Ian Griffiths reports acquiring Silence Therapeutics shares through American Depositary Shares (ADS) on April 24 and 25, 2025.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, filed a Form 4 detailing changes in beneficial ownership.
• On April 24, 2025, Griffiths acquired 90,432 American Depositary Shares (ADS) at a price of $3.42 each.
• These ADS are immediately convertible into 271,296 ordinary shares.
• On April 25, 2025, Griffiths acquired 59,568 ADS at a price of $3.54 each, convertible into 178,704 ordinary shares.
• Following these transactions, Griffiths directly owns 10,461,299 ordinary shares.
• The filing indicates that each ADS is convertible into three ordinary shares with no expiration date.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing share acquisitions by a company director, indicating neutral sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be informative for investors.

Stakeholder Impact

• The increased share ownership by a director could be viewed positively by shareholders, signaling confidence in the company's future.

Key Dates

Keywords

Silence Therapeutics, Richard Ian Griffiths, Form 4, Beneficial Ownership, ADS, American Depositary Shares, Share Acquisition, Director